Growth Hormone Therapy in Neonatal Patients With Methylmalonic Acidemia

Chuan Hong Kao, Mei Ying Liu, Tze Tze Liu, Kwang Jen Hsiao, Kang Hsiang Cheng, Cheng Hung Huang, Hsiang Yu Lin, Dau Ming Niu*

*此作品的通信作者

研究成果: Article同行評審

6 引文 斯高帕斯(Scopus)

摘要

Background: Information regarding growth hormone (GH) therapy in neonatal patients with methylmalonic acidemia (MMA) is lacking. We present our experience with GH therapy in neonatal patients with MMA. Methods: Four neonatal patients with mut0 type MMA were identified through newborn screening for elevated propionylcarnitine (C3) levels. GH therapy (0.6 IU/kg/week, subcutaneously) was prescribed for patient 1 after 1 month of admission, and was prescribed for patients 2, 3 and 4 on the 1st day of admission. We evaluated weight, skin erosion, hospital stay, and serum levels of C3 after GH therapy. Results: All of the neonatal patients with MMA displayed obvious weight gain and distinct improvement in skin erosions after GH therapy. The duration of hospital stay for patients 2, 3 and 4 was reduced compared to that of patient 1. However, the metabolic effects of GH therapy on reducing serum levels of C3 seem to be indeterminate. Conclusion: Our clinical findings suggest that GH therapy has potentially beneficial effects on neonatal patients with MMA.

原文English
頁(從 - 到)462-467
頁數6
期刊Journal of the Chinese Medical Association
72
發行號9
DOIs
出版狀態Published - 9月 2009

指紋

深入研究「Growth Hormone Therapy in Neonatal Patients With Methylmalonic Acidemia」主題。共同形成了獨特的指紋。

引用此